In support of this notion, inhibiting constitutively activated STAT3 resensitizes drug-resistant lymphomas and myelomas to cisplatin, fludarabine, adriamycin, and vinblastine-induced apoptosis [51], and pairing the cyclooxygenase inhibitor ibuprofen with pharmacological system xc- inhibition using sulfasalazine synergistically improves its antitumor efficacy in a murine sarcoma model [76]. The gene discussed is STAT3; the disease is plasma cell myeloma.